Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 621

1.

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.

Shen L, Rørth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, Latini R, Køber L, Anand IS, Carson PE, Granger CB, Komajda M, McKelvie RS, Solomon SD, Staszewsky L, Swedberg K, Huynh T, Zile MR, Jhund PS, McMurray JJV.

Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1535. [Epub ahead of print]

PMID:
31271255
2.

Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.

Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV.

JACC Heart Fail. 2019 Jun;7(6):457-465. doi: 10.1016/j.jchf.2019.02.015. Epub 2019 May 8.

3.

Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.

Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

JACC Heart Fail. 2019 May;7(5):418-427. doi: 10.1016/j.jchf.2018.12.006. Epub 2019 Apr 10.

PMID:
30981744
4.

B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD.

J Am Coll Cardiol. 2019 Mar 26;73(11):1264-1272. doi: 10.1016/j.jacc.2019.01.018. Epub 2019 Mar 4.

PMID:
30846338
5.

Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.

Pirhonen L, Bolin K, Olofsson EH, Fors A, Ekman I, Swedberg K, Gyllensten H.

Pharmacoecon Open. 2019 Mar 1. doi: 10.1007/s41669-019-0126-3. [Epub ahead of print]

6.

Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.

Zile MR, O'Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J.

J Am Coll Cardiol. 2019 Feb 26;73(7):795-806. doi: 10.1016/j.jacc.2018.11.042.

PMID:
30784673
7.

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.

Ferreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):345-351. doi: 10.1002/ejhf.1400. Epub 2019 Feb 15.

PMID:
30768732
8.

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.

Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD.

Eur J Heart Fail. 2019 Mar;21(3):337-341. doi: 10.1002/ejhf.1402. Epub 2019 Feb 11.

9.

Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis.

Dewan P, Rørth R, Jhund PS, Ferreira JP, Zannad F, Shen L, Køber L, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators.

JACC Heart Fail. 2019 Apr;7(4):336-346. doi: 10.1016/j.jchf.2018.11.005. Epub 2019 Feb 6.

10.

Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women.

Dewan P, Rørth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT, Desai AS, Dickstein K, Køber L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

J Am Coll Cardiol. 2019 Jan 8;73(1):29-40. doi: 10.1016/j.jacc.2018.09.081.

11.

Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate.

Chin KL, Collier T, Pocock S, Pitt B, McMurray JJV, van Veldhuisen DJ, Swedberg K, Vincent J, Zannad F, Liew D.

Clin Res Cardiol. 2019 Jul;108(7):806-814. doi: 10.1007/s00392-018-1410-4. Epub 2019 Jan 2.

PMID:
30604047
12.

The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.

Rørth R, Jhund PS, Kristensen SL, Desai AS, Køber L, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV.

Eur J Heart Fail. 2019 Jan;21(1):40-49. doi: 10.1002/ejhf.1359. Epub 2018 Dec 10.

13.

Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.

Dewan P, Jhund PS, Shen L, Petrie MC, Abraham WT, Atif Ali M, Chen CH, Desai AS, Dickstein K, Huang J, Kiatchoosakun S, Kim KS, Køber L, Lai WT, Liao Y, Mogensen UM, Oh BH, Packer M, Rouleau JL, Shi V, Sibulo AS Jr, Solomon SD, Sritara P, Swedberg K, Tsutsui H, Zile MR, McMurray JJV.

Eur J Heart Fail. 2019 May;21(5):577-587. doi: 10.1002/ejhf.1347. Epub 2018 Dec 10.

14.

Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.

Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, Desai AS, Rouleau JL, Swedberg K, Fonarow GC.

JAMA Cardiol. 2018 Nov 28. doi: 10.1001/jamacardio.2018.3957. [Epub ahead of print]

PMID:
30484837
15.

Person-Centered Incontinence Care in Residential Care Facilities for Older Adults With Cognitive Decline: Feasibility and Preliminary Effects on Quality of Life and Quality of Care.

Wijk H, Corazzini K, Kjellberg IL, Kinnander A, Alexiou E, Swedberg K.

J Gerontol Nurs. 2018 Nov 1;44(11):10-19. doi: 10.3928/00989134-20181010-04.

PMID:
30358886
16.

Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al.

Ramires FJA, Martinez F, Gómez EA, Demacq C, Gimpelewicz CR, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV.

ESC Heart Fail. 2018 Dec;5(6):1069-1071. doi: 10.1002/ehf2.12355. Epub 2018 Oct 9. No abstract available.

17.

Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.

Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL; PARADIGM-HF Investigators and Committees.

Eur J Heart Fail. 2018 Dec;20(12):1701-1709. doi: 10.1002/ejhf.1301. Epub 2018 Sep 11.

PMID:
30204280
18.

Effects of a person-centred telephone-support in patients with chronic obstructive pulmonary disease and/or chronic heart failure - A randomized controlled trial.

Fors A, Blanck E, Ali L, Ekberg-Jansson A, Fu M, Lindström Kjellberg I, Mäkitalo Å, Swedberg K, Taft C, Ekman I.

PLoS One. 2018 Aug 31;13(8):e0203031. doi: 10.1371/journal.pone.0203031. eCollection 2018.

19.

Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis.

Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Pannaux M, Swedberg K.

Eur J Heart Fail. 2018 Sep;20(9):1315-1322. doi: 10.1002/ejhf.1234. Epub 2018 Jun 19. Review.

PMID:
29806165
20.

Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).

Vaduganathan M, Patel RB, Mentz RJ, Subacius H, Chatterjee NA, Greene SJ, Ambrosy AP, Maggioni AP, Udelson JE, Swedberg K, Konstam MA, O'Connor CM, Butler J, Gheorghiade M, Zannad F.

Am J Cardiol. 2018 Jul 15;122(2):255-260. doi: 10.1016/j.amjcard.2018.03.362. Epub 2018 Apr 11.

21.

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV.

JACC Heart Fail. 2018 Jun;6(6):489-498. doi: 10.1016/j.jchf.2018.02.004. Epub 2018 Apr 11.

22.
23.

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.

Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD.

JAMA Cardiol. 2018 Jun 1;3(6):498-505. doi: 10.1001/jamacardio.2018.0398.

24.

Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.

Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau JL, Zile MR, Swedberg K, Solomon SD.

JACC Heart Fail. 2018 Jul;6(7):564-569. doi: 10.1016/j.jchf.2018.02.007. Epub 2018 Mar 4.

25.

Engaging patients in their medical care.

Swedberg K.

Eur Heart J. 2018 Feb 14;39(7):494-495. doi: 10.1093/eurheartj/ehy028. No abstract available.

PMID:
29452411
26.

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.

Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD.

Eur J Heart Fail. 2018 Aug;20(8):1230-1239. doi: 10.1002/ejhf.1149. Epub 2018 Feb 12.

PMID:
29431256
27.

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP, Packer M, Rouleau JL, Solomon SD, Claggett BL, Swedberg K, Zile MR, Mueller-Velten G, McMurray JJV.

Eur J Heart Fail. 2018 Apr;20(4):760-768. doi: 10.1002/ejhf.1139. Epub 2018 Feb 12.

28.

Thermally Absorptive Blankets for Highly Efficient Snowbank Melting.

Hansen OL, Sheen AB, Swedberg KM, Vitale KW, Wray SM, Fox MD, Boreyko JB.

Langmuir. 2018 Feb 27;34(8):2606-2609. doi: 10.1021/acs.langmuir.7b03182. Epub 2018 Feb 16.

PMID:
29376373
29.

Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations.

van der Meer P, Grote Beverborg N, Pfeffer MA, Olson K, Anand IS, Westenbrink BD, McMurray JJV, Swedberg K, Young JB, Solomon SD, van Veldhuisen DJ.

Circ Heart Fail. 2018 Feb;11(2):e004431. doi: 10.1161/CIRCHEARTFAILURE.117.004431.

PMID:
29367268
30.

The year in cardiology 2017: heart failure.

Lund LH, Køber L, Swedberg K, Ruschitzka F.

Eur Heart J. 2018 Mar 7;39(10):832-839. doi: 10.1093/eurheartj/ehx782. No abstract available.

PMID:
29300950
31.

Lessons for the monitoring of safety in clinical trials.

Swedberg K.

Eur J Heart Fail. 2018 Jan;20(1):148. doi: 10.1002/ejhf.1085. Epub 2017 Nov 30. No abstract available.

32.

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.

Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukát A, Chen CH, Ramires F, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Solomon SD, Swedberg K, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees.

Eur J Heart Fail. 2018 Mar;20(3):514-522. doi: 10.1002/ejhf.1056. Epub 2017 Nov 30.

33.

Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.

Wolsk E, Claggett B, Køber L, Pocock S, Yusuf S, Swedberg K, McMurray JJV, Granger CB, Pfeffer MA, Solomon SD.

Eur J Heart Fail. 2018 Mar;20(3):504-510. doi: 10.1002/ejhf.1073. Epub 2017 Nov 30.

34.

Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.

Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Køber L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees.

J Am Coll Cardiol. 2017 Nov 14;70(20):2490-2500. doi: 10.1016/j.jacc.2017.09.027.

35.

Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.

Shen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, Abraham WT, Dickstein K, Køber L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees.

Circ Heart Fail. 2017 Nov;10(11). pii: e004361. doi: 10.1161/CIRCHEARTFAILURE.117.004361.

PMID:
29141857
36.

Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.

Böhm M, Komajda M, Borer JS, Ford I, Maack C, Tavazzi L, Moyne A, Swedberg K; SHIFT Investigators.

Eur J Heart Fail. 2018 Feb;20(2):373-381. doi: 10.1002/ejhf.1021. Epub 2017 Oct 12.

37.

Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.

Kristensen SL, Jhund PS, Mogensen UM, Rørth R, Abraham WT, Desai A, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Køber L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators.

Circ Heart Fail. 2017 Oct;10(10). pii: e004409. doi: 10.1161/CIRCHEARTFAILURE.117.004409.

PMID:
29018174
38.

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.

Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray JJV.

Eur J Heart Fail. 2018 Feb;20(2):268-277. doi: 10.1002/ejhf.988. Epub 2017 Sep 27.

39.

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes.

Kristensen SL, Jhund PS, Lee MMY, Køber L, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, McMurray JJV; CHARM Investigators and Committees.

Cardiovasc Drugs Ther. 2017 Dec;31(5-6):545-549. doi: 10.1007/s10557-017-6754-x.

40.

Effects of person-centred care after an event of acute coronary syndrome: Two-year follow-up of a randomised controlled trial.

Fors A, Swedberg K, Ulin K, Wolf A, Ekman I.

Int J Cardiol. 2017 Dec 15;249:42-47. doi: 10.1016/j.ijcard.2017.08.069. Epub 2017 Sep 6.

41.

Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality.

Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, McMurray JJ.

Eur J Heart Fail. 2018 Feb;20(2):295-303. doi: 10.1002/ejhf.901. Epub 2017 Sep 4.

42.

Health-Related Quality of Life Outcomes in PARADIGM-HF.

Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K.

Circ Heart Fail. 2017 Aug;10(8). pii: e003430. doi: 10.1161/CIRCHEARTFAILURE.116.003430.

PMID:
28784687
43.

Declining Risk of Sudden Death in Heart Failure.

Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV.

N Engl J Med. 2017 Jul 6;377(1):41-51. doi: 10.1056/NEJMoa1609758.

44.

Can beta-blockers be used safely in non-cardiac surgery? Important lessons to be learned.

Swedberg K.

Eur Heart J. 2017 Aug 14;38(31):2429-2430. doi: 10.1093/eurheartj/ehx291. No abstract available.

PMID:
28651378
45.

Heart rate and its reduction in chronic heart failure and beyond.

Nikolovska Vukadinović A, Vukadinović D, Borer J, Cowie M, Komajda M, Lainscak M, Swedberg K, Böhm M.

Eur J Heart Fail. 2017 Oct;19(10):1230-1241. doi: 10.1002/ejhf.902. Epub 2017 Jun 19. Review.

46.

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.

Mogensen UM, Køber L, Kristensen SL, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees.

Am Heart J. 2017 Jun;188:35-41. doi: 10.1016/j.ahj.2017.02.034. Epub 2017 Mar 14.

PMID:
28577679
47.

Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.

Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O'Conner C, Levy WC.

J Am Coll Cardiol. 2017 May 30;69(21):2606-2618. doi: 10.1016/j.jacc.2017.03.568.

48.

Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?

Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ.

J Am Coll Cardiol. 2017 May 23;69(20):2542-2550. doi: 10.1016/j.jacc.2017.03.563. Review.

49.

Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years.

Packer M, Pitt B, Rouleau JL, Swedberg K, DeMets DL, Fisher L.

JACC Heart Fail. 2017 Jun;5(6):399-407. doi: 10.1016/j.jchf.2017.03.003. Epub 2017 May 10.

50.

Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.

Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie MC, DeMets D, Kobrin I, Roux S, Swedberg K; ENABLE Investigators and Committees.

JACC Heart Fail. 2017 May;5(5):317-326. doi: 10.1016/j.jchf.2017.02.021. Review.

Supplemental Content

Loading ...
Support Center